128 related articles for article (PubMed ID: 25146330)
1. Analogs of cinnamic acid benzyl amide as nonclassical inhibitors of activated JAK2 kinase.
Mielecki M; Milner-Krawczyk M; Grzelak K; Mielecki D; Krzysko KA; Lesyng B; Priebe W
Curr Cancer Drug Targets; 2014; 14(7):638-51. PubMed ID: 25146330
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of Janus kinases by tyrosine phosphorylation inhibitor, Tyrphostin AG-490.
Rashid S; Bibi N; Parveen Z; Shafique S
J Biomol Struct Dyn; 2015; 33(11):2368-79. PubMed ID: 26017266
[TBL] [Abstract][Full Text] [Related]
3. Cinnamic Acid Derivatives as Inhibitors of Oncogenic Protein Kinases--Structure, Mechanisms and Biomedical Effects.
Mielecki M; Lesyng B
Curr Med Chem; 2016; 23(10):954-82. PubMed ID: 26980568
[TBL] [Abstract][Full Text] [Related]
4. Direct interaction of natural and synthetic catechins with signal transducer activator of transcription 1 affects both its phosphorylation and activity.
Menegazzi M; Mariotto S; Dal Bosco M; Darra E; Vaiana N; Shoji K; Safwat AA; Marechal JD; Perahia D; Suzuki H; Romeo S
FEBS J; 2014 Feb; 281(3):724-38. PubMed ID: 24255956
[TBL] [Abstract][Full Text] [Related]
5. The JAK2 inhibitors CEP-33779 and NVP-BSK805 have high P-gp inhibitory activity and sensitize drug-resistant cancer cells to vincristine.
Cheon JH; Kim KS; Yadav DK; Kim M; Kim HS; Yoon S
Biochem Biophys Res Commun; 2017 Sep; 490(4):1176-1182. PubMed ID: 28669723
[TBL] [Abstract][Full Text] [Related]
6. Development of novel molecular probes of the Rio1 atypical protein kinase.
Mielecki M; Krawiec K; Kiburu I; Grzelak K; Zagórski W; Kierdaszuk B; Kowa K; Fokt I; Szymanski S; Swierk P; Szeja W; Priebe W; Lesyng B; LaRonde-LeBlanc N
Biochim Biophys Acta; 2013 Jul; 1834(7):1292-301. PubMed ID: 23523885
[TBL] [Abstract][Full Text] [Related]
7. WP1066 disrupts Janus kinase-2 and induces caspase-dependent apoptosis in acute myelogenous leukemia cells.
Ferrajoli A; Faderl S; Van Q; Koch P; Harris D; Liu Z; Hazan-Halevy I; Wang Y; Kantarjian HM; Priebe W; Estrov Z
Cancer Res; 2007 Dec; 67(23):11291-9. PubMed ID: 18056455
[TBL] [Abstract][Full Text] [Related]
8. Pharmacophore and docking-based virtual screening approach for the design of new dual inhibitors of Janus kinase 1 and Janus kinase 2.
Jasuja H; Chadha N; Kaur M; Silakari O
SAR QSAR Environ Res; 2014; 25(8):617-36. PubMed ID: 25148044
[TBL] [Abstract][Full Text] [Related]
9. Discovery of novel Jak2-Stat pathway inhibitors with extended residence time on target.
Guan H; Lamb ML; Peng B; Huang S; Degrace N; Read J; Hussain S; Wu J; Rivard C; Alimzhanov M; Bebernitz G; Bell K; Ye M; Zinda M; Ioannidis S
Bioorg Med Chem Lett; 2013 May; 23(10):3105-10. PubMed ID: 23562594
[TBL] [Abstract][Full Text] [Related]
10. Enhancing specificity in the Janus kinases: a study on the thienopyridine JAK2 selective mechanism combined molecular dynamics simulation.
Li JJ; Cheng P; Tu J; Zhai HL; Zhang XY
Mol Biosyst; 2016 Feb; 12(2):575-87. PubMed ID: 26687880
[TBL] [Abstract][Full Text] [Related]
11. WP1066, a novel JAK2 inhibitor, suppresses proliferation and induces apoptosis in erythroid human cells carrying the JAK2 V617F mutation.
Verstovsek S; Manshouri T; Quintás-Cardama A; Harris D; Cortes J; Giles FJ; Kantarjian H; Priebe W; Estrov Z
Clin Cancer Res; 2008 Feb; 14(3):788-96. PubMed ID: 18245540
[TBL] [Abstract][Full Text] [Related]
12. Antimicrobial and antiproliferative activities of novel synthesized 6-(quinolin-2-ylthio) pyridine derivatives with molecular docking study as multi-targeted JAK2/STAT3 inhibitors.
Nafie MS; Mahgoub S; Amer AM
Chem Biol Drug Des; 2021 Mar; 97(3):553-564. PubMed ID: 32920942
[TBL] [Abstract][Full Text] [Related]
13. Discovery of novel selective Janus kinase 2 (JAK2) inhibitors bearing a 1H-pyrazolo[3,4-d]pyrimidin-4-amino scaffold.
Yin Y; Chen CJ; Yu RN; Shu L; Zhang TT; Zhang DY
Bioorg Med Chem; 2019 Apr; 27(8):1562-1576. PubMed ID: 30846405
[TBL] [Abstract][Full Text] [Related]
14. Insights into the Structural Features Essential for JAK2 Inhibition and Selectivity.
Zhao C; Khadka DB; Cho WJ
Curr Med Chem; 2016; 23(13):1331-55. PubMed ID: 27048338
[TBL] [Abstract][Full Text] [Related]
15. NS-018 reduces myeloma cell proliferation and suppresses osteolysis through inhibition of the JAK2 and Src signaling pathways.
Honda A; Kuramoto K; Niwa T; Naito H
Blood Cancer J; 2018 Jun; 8(7):62. PubMed ID: 29941953
[No Abstract] [Full Text] [Related]
16. The impact of binding site waters on the activity/selectivity trade-off of Janus kinase 2 (JAK2) inhibitors.
Egyed A; Bajusz D; Keserű GM
Bioorg Med Chem; 2019 Apr; 27(8):1497-1508. PubMed ID: 30833158
[TBL] [Abstract][Full Text] [Related]
17. Recombinant human erythropoietin attenuates neuronal apoptosis and cognitive defects via JAK2/STAT3 signaling in experimental endotoxemia.
Zhou TF; Yu JG
J Surg Res; 2013 Jul; 183(1):304-12. PubMed ID: 23236988
[TBL] [Abstract][Full Text] [Related]
18. 8-benzyl-4-oxo-8-azabicyclo[3.2.1]oct-2-ene-6,7-dicarboxylic acid (SD-1008), a novel janus kinase 2 inhibitor, increases chemotherapy sensitivity in human ovarian cancer cells.
Duan Z; Bradner J; Greenberg E; Mazitschek R; Foster R; Mahoney J; Seiden MV
Mol Pharmacol; 2007 Nov; 72(5):1137-45. PubMed ID: 17675586
[TBL] [Abstract][Full Text] [Related]
19. The Development and Use of Janus Kinase 2 Inhibitors for the Treatment of Myeloproliferative Neoplasms.
Hobbs GS; Rozelle S; Mullally A
Hematol Oncol Clin North Am; 2017 Aug; 31(4):613-626. PubMed ID: 28673391
[TBL] [Abstract][Full Text] [Related]
20. How Does the L884P Mutation Confer Resistance to Type-II Inhibitors of JAK2 Kinase: A Comprehensive Molecular Modeling Study.
Kong X; Sun H; Pan P; Li D; Zhu F; Chang S; Xu L; Li Y; Hou T
Sci Rep; 2017 Aug; 7(1):9088. PubMed ID: 28831147
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
